Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Palforzia Peanut Allergy Immunotherapy: Aimmune CEO on REMS, Manufacturing

Source: 
Xconomy
snippet: 

Aimmune Therapeutics Inc. is navigating a host of new challenges as it launches Palforzia, the first peanut allergy immunotherapy to be approved by the US Food and Drug Administration. Most notably, it must get physician practices and individual allergists certified to administer the treatment.